As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). 2, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Alexion’s acquisition of Achillion is subject to the approval of Achillion shareholders and satisfaction of customary closing conditions and approval from relevant regulatory agencies, including clearance under the Hart-Scott Rodino Antitrust Improvements Act. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Inhibiting Factor D in the alternative pathway (AP) of the complement system offers the possibility of selectively blocking AP activity and protecting against the destruction of red blood cells, while leaving the rest of the complement system intact to fight infection. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion … Alexion Completes Acquisition of Achillion. StreetInsider.com Top Tickers, 11/11/2019. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. About Paroxysmal Nocturnal Hemoglobinuria (PNH) PNH is primarily a disease of intravascular hemolysis (IVH), where the red blood cell destruction occurs within the blood vessels. ACHN stock has gained 70% today after it was announced that Alexion Pharmaceuticals (NASDAQ:ALXN) would acquire Achillion Pharmaceuticals (NASDAQ:ACHN) in a deal worth $930 million USD. Per terms of the Achillion deal, Alexion would pay in cash $6.30 per share of the target's common stock. As a result, these patients are transfusion dependent despite treatment but do not have bone marrow failure or aplastic anemia. The transaction is expected to close in the first half of 2020. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional … Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. This press release includes forward-looking statements related to Alexion’s acquisition of Achillion, including: the acquisition provides the foundation for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases; the acquisition of Achillion represents important continued momentum in expanding and diversifying our portfolio; oral Factor D inhibition holds great promise in treating multiple rare, complement-mediated diseases, providing the opportunity to significantly expand our portfolio into new therapeutic areas; we are committed to maintaining continuity in the programs currently underway and will be moving quickly to accelerate Achillion’s efforts; and Alexion will continue development of Achillion’s oral Factor D inhibitor portfolio. The AP news staff was not involved in its creation. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. E-mail Address. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to … Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. Phase 3 development is being initiated for danicopan as an add-on therapy for PNH patients with extravascular hemolysis (EVH). In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second anti-FcRn therapy, a second oral Factor D inhibitor and a third complement inhibitor. Today, C3G patients are treated with steroids and broad-acting immunosuppressants to slow the progression of kidney damage. Alexion Pharmaceuticals (ALXN) announced that it would acquire Achillion Pharmaceuticals (ACHN) for approximately $930 million. Oral Factor D inhibitors have demonstrated proof-of-mechanism to interrupt the overactivation of the AP and reduce C3 fragment deposition, providing a potential treatment approach for targeting the underlying cause of C3G. Patients with PNH may experience a wide range of signs and symptoms, such as fatigue, difficulty swallowing, shortness of breath, abdominal pain, erectile dysfunction, dark-colored urine and anemia. View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005516/en/, Alexion Contacts: The most devastating consequence of chronic hemolysis is thrombosis, which can occur in blood vessels throughout the body, damaging vital organs and causing premature death. Alexion has completed the acquisition of Achillion. ... • Video Game Industry in 2021: The Complete Investors Guide. Alexion Completes Acquisition of Achillion 1/28/20 BOSTON--( BUSINESS WIRE )-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. “The acquisition of Achillion adds two clinical-stage Factor D inhibitors to our growing pipeline, representing important continued momentum in expanding and diversifying our portfolio and advancing our mission of transforming the lives of people with rare diseases,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. Forward-Looking Statement This press release includes forward-looking statements related to Alexion’s acquisition of Achillion, including: the acquisition provides the foundation for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases; the acquisition of Achillion represents important continued momentum in expanding and diversifying our portfolio; oral Factor D inhibition holds great promise in treating multiple rare, complement-mediated diseases, providing the opportunity to significantly expand our portfolio into new therapeutic areas; we are committed to maintaining continuity in the programs currently underway and will be moving quickly to accelerate Achillion’s efforts; and Alexion will continue development of Achillion’s oral Factor D inhibitor portfolio. Alexion noted that the deal would also bring in Achillion's cash reserves, which totaled $230 million as of Sept. 30. Inhibiting Factor D in the alternative pathway (AP) of the complement system offers the possibility of selectively blocking AP activity and protecting against the destruction of red blood cells, while leaving the rest of the complement system intact to fight infection. Alexion Completes Acquisition of Achillion February 10, 2020 Michael Crowe Alexion Pharmaceuticals BOSTON–( BUSINESS WIRE )– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. Alexion to Pay 73% Premium on ACHN Stock. The deal adds Alexion’s product portfolio with two clinical-stage oral small molecule Factor D inhibitors. Press release content from Business Wire. Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, progressive, debilitating and life-threatening ultra-rare blood disorder characterized by hemolysis (destruction of red blood cells) that is mediated by uncontrolled activation of the complement system, a component of the body’s immune system. Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion … BOSTON -- (BUSINESS WIRE)--Jul. Under the terms of the agreement, which was announced on October 16, 2019, Alexion will acquire Achillion for an initial consideration of approximately $930 million, or $6.30 per share in cash for each share of Achillion common stock. We look forward to the expertise the Achillion team brings to Alexion, which, combined with our own complement biology and rare disease development and commercialization experience, will enable us to collectively accelerate progress of the development programs. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. BOSTON-- ( BUSINESS WIRE )-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. C5 inhibition addresses the complications of IVH and the increases in LDH that cause thrombosis and even death in patients with PNH. We are committed to maintaining continuity in the programs currently underway and will be moving quickly to advance Achillion’s efforts.”. Alexion Pharmaceuticals Inc on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc in a deal initially valued at $930 … C3G is an ultra-rare kidney disease for which there is no approved treatment. Shares of Achillion rallied on the news. The company, which will now operate as a subsidiary of Alexion, relocated to Montgomery County last year. Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20200128005516/en/, http://www.businesswire.com/news/home/20200128005516/en. The most devastating consequence of chronic hemolysis is thrombosis, which can occur in blood vessels throughout the body, damaging vital organs and causing premature death. Published: Jan 28, 2020. Alexion Pharmaceuticals reached a deal to acquire Achillion Pharmaceuticals for $930 million, pending Achillion shareholder and regulatory approval. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and … We are committed to maintaining continuity in the programs currently underway and will be moving quickly to advance Achillion's efforts.”. This press release and further information about Alexion can be found at: www.alexion.com. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Achillion’s complement platform is focused on advancing oral small molecules that inhibit the AP and can potentially be used in the treatment of immune-related diseases in which complement AP plays a critical role. However, a small portion of patients – less than 10 percent – receiving a C5 inhibitor continue to experience clinical extravascular hemolysis (EVH), where the red blood cell destruction occurs outside the blood vessels. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. Media About Alexion “The acquisition of Achillion adds two clinical-stage Factor D inhibitors to our growing pipeline, representing important continued momentum in expanding and diversifying our portfolio and advancing our mission of transforming the lives of people with rare diseases,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. Oral Factor D inhibitors have demonstrated proof-of-mechanism to interrupt the overactivation of the AP and reduce C3 fragment deposition, providing a potential treatment approach for targeting the underlying cause of C3G. Susan Altschuller, Ph.D., 857-338-8788 Today, C3G patients are treated with steroids and broad-acting immunosuppressants to slow the progression of kidney damage. Under the merger agreement, Achillion will merge into a newly formed, wholly-owned subsidiary of Alexion. View source version on businesswire.com:https://www.businesswire.com/news/home/20200128005516/en/, Senior Director, Corporate CommunicationsInvestors, KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS, INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY, PUB: 01/28/2020 09:29 AM/DISC: 01/28/2020 09:29 AM, http://www.businesswire.com/news/home/20200128005516/en. Megan Goulart, 857-338-8634 Alexion Completes Acquisition of Achillion – Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for … Achillion (NASDAQ: ACHN) was founded in Connecticut 1998 and has 56 employees. A number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the anticipated benefits of the Achillion platform and therapies not being realized; future clinical trials of Achillion products not proving that the therapies are safe and effective to the level required by regulators; decisions of regulatory authorities regarding the adequacy of the research and clinical tests, marketing approval or material limitations on the marketing of Achillion products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions; unanticipated expenses; interruptions or failures in the manufacture and supply of products and product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; the possibility that results of clinical trials are not predictive of safety and efficacy results of products in broader patient populations; the possibility that clinical trials of product candidates could be delayed or terminated prior to completion for a number of reasons; the adequacy of pharmacovigilance and drug safety reporting processes; and a variety of other risks set forth from time to time in Alexion’s or Achillion’s filings with the SEC, including but not limited to the risks discussed in Alexion’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other filings with the SEC and the risks discussed in Achillion’s Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other filings with the SEC. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). “We believe oral Factor D inhibition holds great promise in treating people with multiple rare, complement-mediated diseases, providing the opportunity to significantly expand our portfolio into new therapeutic areas and to help many more patients. Tilmeld dig nu for at se, hvad du går glip af Find personer, du kender hos Achillion Pharmaceuticals, Inc. Alexion’s acquisition of Achillion is subject to the approval of Achillion shareholders and satisfaction of customary closing conditions and approval from … The U.S. Federal Trade Commission greenlighted the deal last week, granting an early termination of the 30-day waiting period set by federal antitrust laws. About Factor D As part of the acquisition, Alexion will also be acquiring the cash currently on Achillion’s balance sheet. Alexion Completes Acquisition of Achillion Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. Senior Director, Corporate Communications, Investors Alexion Pharmaceuticals, a Boston, Massachusetts-based pharmaceutical company focused on rare diseases, has agreed to acquire Achillion Pharmaceuticals, a Blue Bell, Pennsylvania-based clinical-stage biopharmaceutical company focused on developing oral small-molecule Factor D inhibitors for certain rare diseases, for $930 million. This press release and further information about Alexion can be found at: www.alexion.com. About Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, progressive, debilitating and life-threatening ultra-rare blood disorder characterized by hemolysis (destruction of red blood cells) that is mediated by uncontrolled activation of the complement system, a component of the body’s immune system. Alexion Pharmaceuticals is acquiring Achillion Pharmaceuticals for $930 million, a deal that could strengthen its position providing treatments for a rare blood disorder. Alexion Pharmaceuticals Inc. is acquiring Achillion Pharmaceuticals Inc. for cash and contingent value rights (CVRs), which will entitle the former Achillion shareholders to additional cash based on clinical and regulatory thresholds. C5 inhibition addresses the complications of IVH and the increases in LDH that cause thrombosis and even death in patients with PNH. Forward-Looking Statement Potential indications currently being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second anti-FcRn therapy, a second oral Factor D inhibitor and a third complement inhibitor. As of September 30, 2019, this was approximately $230 … The deal amounts to a more than 70% premium over Achillion’s share price at the close of trading yesterday. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe, to Alexion’s … 1. “We believe oral Factor D inhibition holds great promise in treating people with multiple rare, complement-mediated diseases, providing the opportunity to significantly expand our portfolio into new therapeutic areas and to help many more patients. Alexion Pharmaceuticals Inc. announced Tuesday that it has completed its $930 million acquisition of Achillion Pharmaceuticals. Danicopan is also in Phase 2 development for C3G, and ACH-5228 is in Phase 2 development for PNH. About C3 Glomerulopathy (C3G) C3G is an ultra-rare kidney disease for which there is no approved treatment. However, a small portion of patients – less than 10 percent – receiving a C5 inhibitor continue to experience clinical extravascular hemolysis (EVH), where the red blood cell destruction occurs outside the blood vessels. http://www.businesswire.com/news/home/20200128005516/en, © 1985 - 2021 BioSpace.com. Danicopan is also in Phase 2 development for C3G, and ACH-5228 is in Phase 2 development for PNH. Alexion will continue development of Achillion’s oral Factor D inhibitor portfolio, which includes two clinical-stage medicines-in-development – danicopan (ACH-4471) and ACH-5228 – as well as multiple compounds in preclinical development. As a result, these patients are transfusion dependent despite treatment but do not have bone marrow failure or aplastic anemia. Shares of Alexion have gained 2.7% in the year so far against the industry’s decline of 5.1%. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with … The disease is characterized by the deposition of C3 protein fragments in the filtering units (glomeruli) of the kidney, caused by overactivation of the complement alternative pathway (AP). Achillion Pharmaceuticals, Inc. (ACHN): Price and Financial Metrics ... Achillion Pharmaceuticals discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. To acquire Achillion, Alexion has put together a deal worth $930 million upfront. The … As of September 30, 2019, this was approximately $230 million; the actual amount will be determined as of the transaction close. The acquisition … Alexion completes acquisition of Achillion Pharmaceuticals . About Factor D Factor D is an essential serine protease and critical control point in the alternative pathway (AP) of the complement system, a part of the innate immune system.
Berkeley Energia Unternehmen, Andexanet Alfa Cost Uk, Outlet Mall Restaurants, Handball Logo Design, Fürstl Park Inzigkofen, Landratsamt Freiburg Corona, Mary Tudor Film, Mercedes-benz 1114 Ficha Técnica, Fleischkonsum Pro Kopf Weltweit, Basketball Klamotten Damen,